The AP5S1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated via targeted disruption of the AP5S1 gene in the Jurkat host cell background. This product is supplied as a mixed pool of edited cells, providing a heterogeneous population for loss-of-function studies without requiring isolation of single-cell clones. The polyclonal format enables robust representation of edited alleles while mitigating clonal artifacts, making it suitable for population-level analyses of AP5S1-dependent phenotypes.
Jurkat cells are an immortalized human T lymphocyte line originally derived from a patient with T-cell leukemia. They serve as a widely employed model for investigating T-cell receptor (TCR) signaling, apoptosis, and immune cell biology. Their rapid proliferation, stable culture characteristics, and well-characterized signaling networks make them an ideal host for studying endosomal trafficking and autophagy in a lymphocyte context. The Jurkat background is particularly relevant for exploring how AP-5 complex functions intersect with T-cell physiology.
The AP5S1 gene encodes the sigma1 subunit of the adaptor protein complex 5 (AP-5), a heterotetrameric complex that facilitates retrograde trafficking of cargo from late endosomes to the trans-Golgi network. AP5S1 directly interacts with other AP-5 subunits (AP5Z1, AP5M1, AP5B1) and cooperates with SPG11 and SPG15 to mediate sorting of the cation-independent mannose 6-phosphate receptor (CI-MPR). This process is essential for delivering lysosomal hydrolases and promoting autophagic cargo degradation. Mechanistically, the AP-5 complex is regulated by phosphoinositides and clathrin, positioning AP5S1 as a critical node in endosomal-lysosomal pathway homeostasis and autophagic flux.
Disruption of AP5S1 in Jurkat cells provides a powerful model to dissect the role of the AP-5 complex in T-cell endosomal sorting and lysosomal biogenesis. Given that mutations in AP-5 components cause hereditary spastic paraplegia with neurodevelopmental features, this immune cell model offers a complementary system to study disease-relevant trafficking defects. In Jurkat cells, AP5S1 knockout can reveal alterations in CI-MPR localization, lysosomal enzyme trafficking, and autophagy, thereby linking endosomal dysfunction to lymphocyte biology and potentially uncovering immune-related aspects of AP-5-associated disorders.
This polyclonal knockout product supports a broad array of research applications, including examination of AP-5-mediated cargo sorting via CI-MPR immunofluorescence microscopy, assessment of autophagy through LC3 lipidation assays and flow cytometry, and investigation of lysosomal gene expression by RT-qPCR. Co-immunoprecipitation with SPG11 or SPG15 can validate protein interactions, while drug sensitivity profiling enables screening for compounds that modulate lysosomal dysfunction. Researchers can also model hereditary spastic paraplegia pathology in an immune cell context to explore non-neuronal contributions to disease. For additional information or to inquire about custom configurations, please contact Ascent Research.
